EUVIMEDEUVIMED entdecken
CrossrefInfokarte

DOAC Score Versus HAS‐BLED and ORBIT for Predicting Bleeding Events in Atrial Fibrillation on Direct Oral Anticoagulants

Yanfei Guo, Wengen Zhu, Qunfeng Ren

Clinical Cardiology · 2026-05 · 49 (5)

DOI: 10.1002/clc.70315 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background The comparative performance of the DOAC score versus established bleeding risk scores in patients with atrial fibrillation (AF) receiving direct oral anticoagulants (DOACs) remains uncertain. This meta‐analysis evaluated the predictive ability of the DOAC score compared with HAS‐BLED and ORBIT. Methods PubMed and Embase were systematically searched to identify studies assessing the predictive performance of the DOAC score in AF patients treated with DOACs. Pooled C‐indices were calculated to compare discrimination. Reclassification metrics (net reclassification improvement [NRI], integrated discrimination improvement [IDI]), calibration analyses, and decision curve analyses (DCA) were synthesized qualitatively. Results Nine studies comprising 12 cohorts were included ( n = 89 688). The DOAC score demonstrated significantly superior discrimination for major bleeding compared with HAS‐BLED (C‐index 0.68 vs. 0.63). No significant differences were observed for intracranial hemorrhage, gastrointestinal bleeding, or clinically relevant non‐major bleeding, nor in comparisons with ORBIT. Reclassification analyses showed heterogeneous findings, with several studies reporting no incremental benefit of the DOAC score, although one large cohort demonstrated improved NRI and IDI over HAS‐BLED. Calibration analyses revealed good performance across scores, though both HAS‐BLED and DOAC tended to overestimate bleeding risk in high‐risk groups. DCA suggested variable but occasionally greater net benefit of the DOAC score at clinically relevant risk thresholds. Conclusions The DOAC score provides modest but statistically significant improvement in predicting major bleeding compared with HAS‐BLED, with comparable performance to ORBIT. However, reclassification, calibration, and clinical utility vary across settings, underscoring the need for further prospective validation.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →